Patents by Inventor Lars HILLRINGHAUS
Lars HILLRINGHAUS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240377388Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.Type: ApplicationFiled: May 21, 2024Publication date: November 14, 2024Inventors: Michael GERG, Dieter HEINDL, Lars HILLRINGHAUS, Klaus HIRZEL, Caroline Dorothea HOJER, Florian HUBER, Hans-Peter JOSEL, Thomas MEIER, Michael SCHRAEML, Edgar VOSS
-
Patent number: 12025613Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as discloed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.Type: GrantFiled: December 15, 2021Date of Patent: July 2, 2024Assignee: Roche Diagnostics Operations, Inc.Inventors: Michael Gerg, Dieter Heindl, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Florian Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Edgar Voss
-
Publication number: 20240209432Abstract: The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.Type: ApplicationFiled: June 28, 2023Publication date: June 27, 2024Applicant: Roche Sequencing Solutions, Inc.Inventors: Frank BERGMANN, Christoph SEIDEL, Andrew TRANS, Dmitriy GREMYACHINSKIY, Hannes KUCHELMEISTER, Lars HILLRINGHAUS
-
Publication number: 20240150824Abstract: The present disclosure relates to tagged nucleoside-5?-oligophosphates having a positively charged polymer tag structure and components thereof. Such nucleoside-5?-oligophosphates are useful, for example, in nanopore-based sequencing-by-synthesis applications. Also disclosed herein are nanopore constructs engineered to have additional negatively-charged moieties in the channel of the nanopore. Such nanopores can be useful, for example, for providing a repellant force against template and/or primer nucleic acids inserting into the pore during a nucleic sequence-by-synthesis process. The tagged nucleoside-5?-oligophosphates and nanopores disclosed herein can be used together to provide nanopore-based nucleic acid sequencing-by-synthesis systems and processes having reduced background tag levels and improved throughput.Type: ApplicationFiled: August 9, 2021Publication date: May 9, 2024Inventors: Aruna Ayer, Frank Bergmann, Peter Crisalli, Lars Hillringhaus, Omid Khakshoor, Hannes Kuchelmeister, Rongxin Nie, Marshall W. Porter, Christoph Seidel, Seong-Ho Shin, Meng Taing, Adolfo Vargas
-
Publication number: 20230358748Abstract: Herein is reported a method for determining the presence of hydrolase activity in a sample by incubating the sample in a buffered solution, which comprises an artificial hydrolase substrate that comprises an ester bond covalently linking an alcohol residue, which is conjugated to a label for removal, and a carboxylic acid residue, which is conjugated to a capture and detection label, as well as bovine serum albumin, and thereafter determining or quantifying, respectively, the released carboxylic acid in the free alcohol depleted incubation mixture.Type: ApplicationFiled: December 16, 2022Publication date: November 9, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Franziska EDELMANN, Roberto FALKENSTEIN, Tobias GRAF, Sanjay GUPTA, Lars HILLRINGHAUS, Tarik Ali KHAN, Michael LEISS, Thomas MEIER, Michael WIEDMANN
-
Publication number: 20230340147Abstract: The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to ?-1,6-core-fucosylated prostate specific antigen (PSA) and partial sequences thereof comprising the ?-1,6-core-fucose residue. The antibodies and antigen binding fragments significantly discriminate between core-fucosylated PSA or core-fucosylated PSA partial sequences and other glycosylated PSA species and partial sequences thereof lacking the core-fucose residue, including aglycosylated PSA, as well as core-fucosylated glycan in other contexts. The present invention further relates to nucleic acid molecules encoding the light chain variable region or the heavy chain variable region of the antibody of the invention, as well as vectors comprising said nucleic acid molecules.Type: ApplicationFiled: March 21, 2023Publication date: October 26, 2023Inventors: Magdalena Swiatek-de Lange, Joanna Siebenhaar, Carol Jones, Thomas Pritchett, Andrea Muranyi, Caroline Dorothea Hojer, Michael Gerg, Lars Hillringhaus, Gloria Tabares, Christian Roessler, Michael Schraeml, Shalini Singh, Theresa Kott
-
Publication number: 20230333095Abstract: The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a kit, a complex, a method to synthesize a complex and the use thereof for detecting the analyte of interest in the sample.Type: ApplicationFiled: June 22, 2023Publication date: October 19, 2023Inventors: Maksim Fomin, Dieter Heindl, Lars Hillringhaus, Hannes Kuchelmeister, Mohamed Yosry Hassan Mohamed, Tobias Oelschlaegel, Sona Simonyiova
-
Patent number: 11739378Abstract: The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.Type: GrantFiled: March 15, 2021Date of Patent: August 29, 2023Assignees: Roche Sequencing Solutions, Inc., Roche Molecular Systems, Inc.Inventors: Frank Bergmann, Christoph Seidel, Andrew Trans, Dmitriy Gremyachinskiy, Hannes Kuchelmeister, Lars Hillringhaus
-
Publication number: 20230095167Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.Type: ApplicationFiled: February 19, 2021Publication date: March 30, 2023Inventors: Alfred Engel, Michael Gerg, Ute Jucknischke, Johann Karl, Peter Kastner, Thomas Meier, Lars Hillringhaus, Ulrich Schotten, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, André Ziegler, Roberto Latini, Jennifer Marie Theresia Anna Meessen
-
Publication number: 20230055005Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.Type: ApplicationFiled: August 24, 2022Publication date: February 23, 2023Inventors: Bernhard Eckert, Michael Gerg, Johann Karl, Martin Kaufmann, Julia Riedlinger, Magdelena Swiatek-de-Lange, Lars Hillringhaus, Klaus Hirzel, Marcus-Rene Lisy
-
Patent number: 11466098Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.Type: GrantFiled: January 13, 2020Date of Patent: October 11, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Bernhard Eckert, Michael Gerg, Johann Karl, Martin Kaufmann, Julia Riedlinger, Magdelena Swiatek-de Lange, Lars Hillringhaus, Klaus Hirzel, Marcus-Rene Lisy
-
Publication number: 20220107310Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.Type: ApplicationFiled: December 15, 2021Publication date: April 7, 2022Inventors: Michael GERG, Dieter HEINDL, Lars HILLRINGHAUS, Klaus HIRZEL, Caroline Dorothea HOJER, Florian HUBER, Hans-Peter JOSEL, Thomas MEIER, Michael SCHRAEML, Edgar VOSS
-
Publication number: 20220106408Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.Type: ApplicationFiled: December 15, 2021Publication date: April 7, 2022Inventors: Michael GERG, Lars HILLRINGHAUS, Klaus HIRZEL, Caroline Dorothea HOJER, Hans-Peter JOSEL, Christoph SEIDEL, Michael SCHRAEML, Leopold VON PROFF
-
Publication number: 20220090189Abstract: The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.Type: ApplicationFiled: March 15, 2021Publication date: March 24, 2022Applicant: Roche Sequencing Solutions, Inc.Inventors: Frank BERGMANN, Christoph SEIDEL, Andrew TRANS, Dmitriy GREMYACHINSKIY, Hannes KUCHELMEISTER, Lars HILLRINGHAUS
-
Patent number: 10975426Abstract: The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.Type: GrantFiled: August 26, 2016Date of Patent: April 13, 2021Assignee: Roche Sequencing Solutions, Inc.Inventors: Frank Bergmann, Christoph Seidel, Andrew Trans, Dmitriy Gremyachinskiy, Hannes Kuchelmeister, Lars Hillringhaus
-
Publication number: 20200140569Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.Type: ApplicationFiled: January 13, 2020Publication date: May 7, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Bernhard Eckert, Michael Gerg, Johann Karl, Martin Kaufmann, Julia Riedlinger, Magdelena Swiatek-de Lange, Lars Hillringhaus, Klaus Hirzel, Marcus-Rene Lisy
-
Publication number: 20190324025Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.Type: ApplicationFiled: June 24, 2019Publication date: October 24, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Michael Gerg, Dieter Heindl, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Florian Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Edgar Voss
-
Publication number: 20190309091Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.Type: ApplicationFiled: June 24, 2019Publication date: October 10, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Michael Gerg, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Hans-Peter Josel, Christoph Seidel, Michael Schraeml, Leopold Von Proff
-
Publication number: 20190002968Abstract: The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.Type: ApplicationFiled: August 26, 2016Publication date: January 3, 2019Inventors: Frank BERGMANN, Christoph SEIDEL, Andrew TRANS, Dmitriy GREMYACHINSKIY, Hannes KUCHELMEISTER, Lars HILLRINGHAUS
-
Publication number: 20180078655Abstract: The present invention relates to immunoconjugates for specific induction of T cell cytotoxicity against a target cell, comprising at least one T cell response eliciting peptide that is presentable via MHC class I coupled to a target cell binding moiety via a cleavable bond and methods of their production and uses thereof.Type: ApplicationFiled: August 17, 2017Publication date: March 22, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Sebastian DZIADEK, Alexander LIFKE, Valeria LIFKE, Lars HILLRINGHAUS